CVL237 Tablets for APDS/PASLI

Summary

This study was designed to evaluate the efficacy and safety of CVL237 tablets in patients with APDS/PASLI (activated phosphoinositol 3-kinase δ syndrome /p110 delta-activated mutation leading to senescent T cells, lymphadenopathy, and immune deficiency).

Timeline

Start

2024-03-30

Primary completion

2025-12-29

Completion

2026-03-30

Drugs

Indications